Swan Venture Fund — 2017 Investments
1 investments dated 2017 · listed companies and verified rows first · show all
Opticyteopticyte.cominSep 2017
Opticyte develops the VitalO₂, a preclinical-stage medical device aimed at hospitals, with an FDA De Novo pathway and Breakthrough Device Designation.
BiotechHealthtechMedical DevicesSeattle, US
Lori Arakaki(Founder)inRobert Masterson(Executive Officer, Director, Promoter)Kenneth Schenkman(Executive Officer, Director, Promoter)Lorilee Arakaki(Executive Officer, Director, Promoter)
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.